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Abstract
Background: The ProtecT trial reported intention-to-treat analysis of men with localised
prostate cancer randomly allocated to active monitoring (AM), radical prostatectomy,
and external beam radiotherapy.
Objective: To report outcomes according to treatment received in men in randomised
and treatment choice cohorts.
Design, setting, and participants: This study focuses on secondary care. Men with
clinically localised prostate cancer at one of nine UK centres were invited to participate
in the treatment trial comparing AM, radical prostatectomy, and radiotherapy.y Drs. Donovan, Hamdy, Lane, Metcalfe, and Neal contributed equally.
z Sadly, Professor Doug Altman passed away while this paper was being completed.
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Intervention: Two cohorts included 1643 men who agreed to be randomised and
997 who declined randomisation and chose treatment.
Outcome measurements and statistical analysis: Analysis was carried out to assess
mortality, metastasis and progression and health-related quality of life impacts on
urinary, bowel, and sexual function using patient-reported outcome measures. Analysis
was based on comparisons between groups deﬁned by treatment received for both
randomised and treatment choice cohorts in turn, with pooled estimates of intervention
effect obtained using meta-analysis. Differences were estimated with adjustment for
known prognostic factors using propensity scores.
Results and limitations: According to treatment received, more men receiving AM died
of PCa (AM 1.85%, surgery 0.67%, radiotherapy 0.73%), whilst this difference remained
consistent with chance in the randomised cohort (p = 0.08); stronger evidence was found
in the exploratory analyses (randomised plus choice cohort) when AM was compared
with the combined radical treatment group (p = 0.003). There was also strong evidence
that metastasis (AM 5.6%, surgery 2.4%, radiotherapy 2.7%) and disease progression (AM
20.35%, surgery 5.87%, radiotherapy 6.62%) were more common in the AM group.
Compared with AM, there were higher risks of sexual dysfunction (95% at 6 mo) and
urinary incontinence (55% at 6 mo) after surgery, and of sexual dysfunction (88% at 6 mo)
and bowel dysfunction (5% at 6 mo) after radiotherapy. The key limitations are the
potential for bias when comparing groups deﬁned by treatment received and changes in
the protocol for AM during the lengthy follow-up required in trials of screen-detected
PCa.
Conclusions: Analyses according to treatment received showed increased rates of dis-
ease-related events and lower rates of patient-reported harms in men managed by AM
compared with men managed by radical treatment, and stronger evidence of greater PCa
mortality in the AM group.
Patient summary: More than 95 out of every 100 men with low or intermediate risk
localised prostate cancer do not die of prostate cancer within 10 yr, irrespective of
whether treatment is by means of monitoring, surgery, or radiotherapy. Side effects on
sexual and bladder function are better after active monitoring, but the risks of spreading
of prostate cancer are more common.
© 2019 The Author(s). Published by Elsevier B.V. on behalf of European Association of
Urology. This is an open access article under the CC BY-NC-ND license (http://creati-
vecommons.org/licenses/by-nc-nd/4.0/).
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Clinically localised prostate cancer detected by prostate-
specific antigen (PSA) testing is a common problem with
164 690 men in the USA diagnosed in 2017 and 29 430 dying
of the disease [1]. Management of men with low- or
intermediate-risk disease [2] remains problematic for
patients and clinicians [2,3]. It is recognised that many
men with low- or intermediate-risk disease do not benefit
from immediate radical intervention, although recent studies
have shown improved future outcomes in high-risk men [4].
The UK National Institute for Health Research, Health
Technology Assessment ProtecT study compared active
monitoring (AM), surgery (radical prostatectomy [RP]), and
radiotherapy (RT) for men aged 50–69 yr with localised
prostate cancer detected through community-based PSA
testing [5,6]. All 2664 men eligible to participate in the
randomised controlled trial (RCT) were followed up
identically [6]. A total of 1643 (62%) men agreed to be
randomised (“randomised cohort”), and 997 men declined
randomisation and chose treatment (“treatment choice
cohort”) [7]. Of the 1643 randomised, 22% did not receive
their allocated treatment (16% AM, 28% RP, and 23% RT) [7].
Intention-to-treat (ITT) analysis gives unbiased esti-
mates of differences in outcome between allocated treat-
ments, but may underestimate differences between patient
groups defined by treatment received [8–10]. This paper
presents an analysis of groups defined according toPlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.030treatment received in the randomised and treatment choice
cohorts. Such analyses can be informative to individual
patients considering which treatment to undergo, but
groups defined by treatment received may not be compa-
rable, as patients with less favourable prognoses may opt for
more radical treatment, resulting in “confounding by
indication”. The analysis presented here attempted to
control that confounding using a propensity score approach.
2. Patients and methods
2.1. Study design and participants
In brief, men with clinically localised prostate cancer at one of nine UK
centres were invited toparticipate in the treatment trial comparing AM, RP,
and RT [11]. Approval was obtained from the UK Trent Multicentre Ethics
Committee (01/4/025; trial registration ISRCTN20141297, NCT02044172).
The primary analysis was reported at 10-yr follow-up [2,3,11].
2.2. Interventions, definitions of “treatment received”, and
follow-up
Men managed by AM had PSA measured 3 monthly in the 1st year and 6–
12 monthly thereafter. An increase of 50% or more in PSA over a 12-mo
period triggered a clinical review. During RP, men with a PSA level of
10 mg/l or a Gleason score of 7 underwent lymphadenectomy.
Adjuvant RT was considered for positive margins or extracapsular
disease. The RT protocol included neoadjuvant androgen deprivation
therapy (ADT) for 3–6 mo before and concomitantly with three-ty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
Table 1 – Baseline characteristics of men in the randomised cohort
and treatment choice cohort, in groups defined by the completion
of curative surgery or radiotherapy, or remaining on protocol
active monitoring for 12 mo after diagnosis
Randomised
cohort
Treatment choice
cohort
Median age in years (Q1, Q3), n
Active monitoring 63 (59, 67), 628 63 (59, 66), 507
Surgery 62 (58, 66), 488 62 (58, 65), 262
Radiotherapy 62 (58, 66), 491 63 (59, 66), 189
Managerial occupation (%)
Active monitoring 260/621 (42) 256/496 (52)
Surgery 207/482 (43) 142/259 (55)
Radiotherapy 204/482 (42) 91/186 (49)
Median PSA in ng/ml (Q1, Q3), n
Active monitoring 4.4 (3.6, 6.4), 628 4.6 (3.5, 6.5), 507
Surgery 4.7 (3.7, 6.9), 488 4.9 (3.7, 6.8), 262
Radiotherapy 4.7 (3.7, 6.9), 491 5.0 (3.8, 7.3), 189
PSA >10 ng/ml (%)
Active monitoring 53/628 (8.4) 34/507 (6.7)
Surgery 41/488 (8.4) 26/262 (9.9)
Radiotherapy 51/491 (10) 28/189 (15)
Gleason grade group 1 (%)
Active monitoring 503/628 (80) 417/507 (82)
Surgery 366/488 (75) 186/262 (71)
Radiotherapy 370/491 (75) 123/189 (65)
Gleason grade group 3 and higher (%)
Active monitoring 30/628 (4.8) 17/507 (3.4)
Surgery 27/488 (5.5) 18/262 (6.9)
Radiotherapy 42/491 (8.6) 14/189 (7.4)
Clinical stage T2 (%)
Active monitoring 137/628 (22) 108/507 (21)
Surgery 127/488 (26) 70/261 (27)
Radiotherapy 121/491 (25) 50/189 (26.5)
Low-risk disease (%)a
Active monitoring 409/580 (71) 352/473 (74)
Surgery 293/447 (66) 146/239 (61)
Radiotherapy 298/451 (66) 88/171 (51)
PSA = prostate-speciﬁc antigen.
a For approximately 8% of men with T2 disease, no information was available
on whether their tumour stage was T2a, T2b, or T2c, preventing risk
categorisation according to the D’Amico scheme; these men are omitted for
this measure.
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to have received each of the treatments according to the following
deﬁnitions; men who did not fulﬁl these were excluded:
1. AM if there were two or more PSA tests and no radical treatment in the
12 mo following diagnosis
2. Surgery (RP) if RP was carried out within 12 mo following diagnosis
3. RT if treatment protocol was started within 12 mo and completed
within 15 mo; men who underwent brachytherapy within 12 mo of
diagnosis were included in the RT arm
Follow-up was standardised according to treatment-speciﬁc path-
ways. In all groups, ADT was offered when serum PSA reached a
concentration of 20 mg/l (or less if clinically indicated). Skeletal imaging
was carried out if PSA was 10 mg/l.
2.3. Outcomes
Cause of death was determined as previously reported [2]. Metastatic
disease was deﬁned as bony, visceral, or lymph node metastases, or PSA
levels above 100 mg/l. Progression included metastases, clinical T3 or T4
disease, long-term ADT, ureteric obstruction, rectal ﬁstula, or need for
urinary catheter due local tumour growth. Initiation of ADT is presented
separately as a more objective marker of disease progression.
Cancer grades were classiﬁed into the following Gleason grade
groups: (1) 3 + 3 = 6; (2) 3 + 4 = 7; (3) 4 + 3 = 7; (4) 4 + 4 = 8, 3 + 5 = 8, 5
+ 3 = 8; and (5) 9. We combined the prognostic factors into a single
“D’Amico” score: men in Gleason grade group 1, with PSA 10 mg/l, and
having clinical stage T2a were of low risk [12–14].
Health-related quality of life impacts on urinary, bowel, and sexual
function were assessed using patient-reported outcome measures
(PROMs) including the Expanded Prostate Index Composite (EPIC [15])
and the International Continence Society Male Short Form (ICSmaleSF
[16]). We present these two PROMs completed at recruitment, 6 mo, and
annually following randomisation; urinary incontinence was assessed by
daily pad use over the preceding 4 wk (EPIC), nocturia two or more times
per night (ICSmaleSF), potency (EPIC), and blood in stools at least half the
time (EPIC). ICSmaleSF was included during the entire course of the trial
and the EPIC instrument was used from 2005.
2.4. Statistical analysis
The analysis plan included a secondary analysis of the randomised cohort
based on treatment received [17]. This prespeciﬁed secondary analysis
accommodated multiple testing: if an overall test of event rates across
the three groups gave evidence of a difference, this was followed by
pairwise tests of RP versus AM and RT versus AM. The other analyses
presented in this paper should be considered exploratory.
We compared outcome event rates using proportional hazard
regression, with two propensity scores included as covariates. Methods
based on the complier average causal effect approach offer better control
of confounding by indication, as they control by known and unknown
prognostic factors. We used a propensity score approach because it was
straightforward generalisation for comparisons between three groups,
we could use the same method for the randomised and treatment choice
cohorts, and it was difﬁcult to apply the prespeciﬁed instrumental
variable methods in the current context of complex movements between
treatments and the absence of a “usual care” control group.
The propensity score approach was applied to both the randomised
and the choice cohort for treatment received. The propensity scores were
generated using multinomial logistic regression, with treatment
received as the three-category outcome variable, and the following
covariates: cT stage (1 or 2), Gleason grade group (1, 2, 3, and >3 [4 andPlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.0305 combined]), log-transformed PSA, age in years, and study centre. The
scores were generated for each man from the model-ﬁtted values, to give
probabilities of undergoing RP rather than AM and RT, and the
probability of undergoing RT rather than AM and RP.
Hazard ratios for comparisons between RP and AM, and between RT
and AM are presented for the randomised and treatment choice cohorts.
The time scale started on the day of allocation. By deﬁnition, men in
treatment-received groups cannot have an (outcome) event between
diagnosis and meeting the group criteria; consequently, men became “at
risk” at the second PSA test in the AM group, on the day of surgery in the
RP group, and on the 1st day of the protocol in the RT group.
The weighted mean for each treatment comparison is presented
(“pooled” estimate) with weighting by the inverse of the variance of the
estimates (“ﬁxed-effect” meta-analysis). Data from the two cohorts were
combined, and survival curves for prostate cancer mortality and
metastasis calculated from the nonparametric baseline hazard estimate
of proportional hazard regression models, each model having an
additional covariate to distinguish between the randomised and choice
cohorts.
For the PROMs, data from the cohorts were combined, and all data
after treatment were compared between treatment groups; a likelihood-
ratio test quantiﬁed evidence against the null hypothesis of equal
response over 6 yr of follow-up across the three treatment groups. Two-ty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
Fig. 1 – Amongst men who were managed on active monitoring with at least two PSA measurements within 12 mo following diagnosis, the Kaplan-
Meier estimates of cumulative probability of moving to a radical treatment subsequent to the second PSA test (time zero) in the randomised cohort
(solid red line, n = 628) and the choice cohort (dashed blue line, n = 507). PSA = prostate-specific antigen.
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assessments, with Gaussian distributed random effects. All models
included the same propensity measures employed in the analyisis of the
clinical event outcomes, and an additional covariate distinguishing men
in the randomised and choice cohorts. Missing data were not imputed;
all data from men with at least one measure available were included. The
random-effect models provided unbiased estimates of treatment
comparisons, on the assumption that any systematic determinant of
missing data was predictable from the covariates in the model, such as
treatment group or earlier measures of outcome (ie, data were “missing
at random”) [18]. All analyses were performed with Stata software,
version 15.1 (StataCorp, College Station, TX, USA).
3. Results
Of the 1643 men who agreed to randomisation (randomised
cohort), 1260 (78%) received the allocated treatment; the
remaining men chose other treatments. The 997 men who
declined randomisation and chose treatments (treatmentPlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.030choice cohort: AM 507 [51%], RP 262 [26%], RT per protocol
125 [13%], other RT including brachytherapy 64 [6%], and
39 other treatments or no treatments completed within the
predefined time limits).
In the randomised cohort, 628 men were managed by
AM, undergoing at least two PSA tests in their first 12 mo
of monitoring. These men remained on monitoring for a
median of 7.7 yr (90% range 1.8–13.1 yr) and underwent a
median of 3.3 tests per year (90% range 2.1–4.7 tests per
year). In the treatment choice cohort, 507 men underwent
at least two PSA tests in their first 12 mo of monitoring,
and were comparable with men in the randomised cohort
in remaining on monitoring for a median of 7.5 yr (90%
range 1.7–13.1 yr) and undergoing a median of 3.2 tests
per year (90% range 2.0–4.6 tests per year). It is clear that
in both cohorts, the vast majority of men managed by AM
were undergoing more than the minimum of one PSA test
every 12 mo.ty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
Table 2 – For men in the randomised cohort, clinical outcomes for groups defined by random allocation (ie, an intention-to-treat analysis),
and for men in the randomised cohort and treatment choice cohort, clinical outcomes for groups defined by treatment received
Treatment group as deﬁned in the ﬁrst column
Events/N (rate/1000 person years)
p valuea
Active monitoring Surgery Radiotherapy
Prostate cancer death—randomised cohort
Randomised groups 8/545 (1.5) 5/553 (0.92) 4/545 (0.75) 0.50
Treatment receivedb 11/628 (1.8) 2/488 (0.43) 4/491 (0.85) 0.08
Prostate cancer death—treatment choice cohort
Treatment received 10/507 (2.2) 3/262 (1.2) 1/189 (0.57) 0.05
Metastatic disease or prostate cancer death—randomised cohort
Randomised groups 33/545 (6.1) 13/553 (2.4) 16/545 (3.0) 0.004
Treatment received 36/628 (6.0) 10/488 (2.2) 15/491 (3.2) 0.001
Metastatic disease or prostate cancer death—treatment choice cohort
Treatment received 28/507 (6.1) 8/262 (3.3) 3/189 (1.7) <0.001
Disease progression—randomised cohort
Randomised groups 112/545 (20) 46/553 (8.5) 46/545 (8.6) <0.001
Treatment received 142/628 (24) 26/488 (5.6) 30/491 (6.3) <0.001
Disease progression—treatment choice cohort
Treatment received 79/507 (17) 18/262 (7.5) 15/189 (8.5) <0.001
Hormone treatment—randomised cohort
Randomised groups 47/545 (8.7) 26/553 (4.8) 30/545 (5.6) 0.024
Treatment received 53/628 (8.8) 22/488 (4.8) 25/491 (5.3) 0.002
Hormone treatment—treatment choice cohort
Treatment received 30/507 (6.5) 11/262 (4.6) 11/189 (6.2) 0.19
All death—randomised cohort
Randomised groups 59/545 (11) 55/553 (10) 55/545 (10) 0.87
Treatment received 64/628 (11) 45/488 (9.7) 55/491 (12) 0.90
All death—treatment choice cohort
Treatment received 54/507 (12) 23/262 (9.6) 17/189 (9.6) 0.41
a All p values are for a test of the null hypothesis “equal outcome across the three treatment groups”, calculated using proportional hazard regression including
the two propensity scores as covariates.
b This is a prespecified secondary analysis.
Table 3 – Estimated hazard ratios comparing each pair of treatments in turn: the groups are defined by “treatment received” with
adjustment by propensity score to reduce confounding by indication
Surgery versus active
monitoring
Radiotherapy versus
active monitoring
Radiotherapy versus
surgery
Hazard ratio
(95% conﬁdence interval)
p value Hazard ratio
(95% conﬁdence interval)
p value Hazard ratio
(95% conﬁdence interval)
p value
Prostate cancer death
Randomised cohort 0.24 (0.05, 1.07) 0.45 (0.14, 1.41) 1.89 (0.34,10.38)
Treatment choice cohort 0.39 (0.10, 1.49) 0.14 (0.02, 1.15) 0.35 (0.03, 3.59)
Pooled estimate 0.32 (0.12, 0.87) 0.026 0.34 (0.12, 0.92) 0.034 1.07 (0.27, 4.30) 0.9
Metastatic disease or prostate cancer death
Randomised cohort 0.31 (0.16, 0.64) 0.48 (0.26, 0.89) 1.54 (0.69, 3.43)
Treatment choice cohort 0.35 (0.15, 0.78) 0.18 (0.05, 0.62) 0.52 (0.13, 2.03)
Pooled estimate 0.33 (0.19, 0.55) <0.001 0.40 (0.23, 0.69) 0.001 1.17 (0.59, 2.34) 0.7
Disease progression
Randomised cohort 0.19 (0.12, 0.29) 0.20 (0.13, 0.29) 1.05 (0.62, 1.78)
Treatment choice cohort 0.31 (0.18, 0.53) 0.32 (0.18, 0.57) 1.04 (0.51, 2.09)
Pooled estimate 0.23 (0.16, 0.33) <0.001 0.23 (0.17, 0.32) <0.001 1.05 (0.69, 1.60) 0.8
Hormone treatment
Randomised cohort 0.47 (0.28, 0.77) 0.51 (0.32, 0.83) 1.09 (0.61, 1.95)
Treatment choice cohort 0.54 (0.26, 1.09) 0.73 (0.35, 1.50) 1.36 (0.57, 3.26)
Pooled estimate 0.49 (0.33, 0.74) 0.001 0.57 (0.38, 0.85) 0.005 1.17 (0.72, 1.89) 0.5
All death
Randomised cohort 0.97 (0.66, 1.42) 1.06 (0.74, 1.52) 1.09 (0.74, 1.63)
Treatment choice cohort 0.77 (0.46, 1.28) 0.73 (0.42, 1.29) 0.95 (0.49, 1.82)
Pooled estimate 0.89 (0.66, 1.21) 0.5 0.95 (0.70, 1.29) 0.7 1.05 (0.75, 1.47) 0.8
Estimates for the randomised and treatment choice cohorts are combined as a “pooled estimate”.
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Fig. 2 – Prostate cancer-specific survival curves (derived from the proportional hazard regression model) for groups defined by receiving active
monitoring (green), surgery (red), and radiotherapy (blue), with corresponding groups combined across randomised and treatment choice cohorts.
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shown in Table 1 (with all Gleason grade groups presented
in Supplementary Table 1). The vast majority underwent
one of the study treatments as defined previously, with just
36/1643 (2.2%) and 39/997 (3.9%) of men in the randomised
and choice cohorts, respectively, not included in the three
defined treatment groups. The two cohorts differed in a
greater proportion of men in managerial occupations in the
choice cohort. Selection biases were evident, with men with
higher-risk grade and stage disease being more likely to
undergo radical treatments than AM [7].
Fig. 1 presents the Kaplan-Meier estimate of the
probability of moving to radical treatment from AM over
a median of 10 yr. Very similar rates were observed in the
randomised and treatment choice cohorts, with around 45%
of men in both having moved to radical treatment within
10 years.
Table 2 includes clinical outcomes for randomly allocat-
ed groups with the initial ITT comparison adjusted for thePlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.030propensity scores. Outcomes are then presented for treat-
ment-received groups in both the randomised and the choice
cohort. While absolute differences are small, there is strong
evidence of increased metastatic disease, disease progression,
and initiation of ADT for AM compared with surgery and RT.
The risks of disease-specific and all-cause death remain low
and consistent with chance. Risks of these adverse clinical
outcomes for treatment received in both the randomised and
the choice cohort are similar, the exceptions being lower rates
of disease progression and ADT in the treatment-choice group
managed by AM. Supplementary Table 2 presents clinical
outcomes by treatment-received group and Gleason grade
group at diagnosis.
Most progression was development of a high stage (T3 or
T4) or starting of ADT, and was higher in the AM group (60%
[85/142] in the randomised cohort and 57% [45/79] in the
choice cohort). The presence of stage T3 or T4 did not prevent
subsequent radical treatment in some men, with 20% (22/
112) undergoing RP and 35% (39/112) undergoing RT.ty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
Fig. 3 – Proportions free of metastatic disease (derived from the proportional hazard regression model) for groups defined by receiving active
monitoring (green), surgery (red), and radiotherapy (blue), with corresponding groups combined across randomised and treatment choice cohorts.
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received in the randomised and choice cohorts separately,
with the corresponding results from the two cohorts then
being pooled. The pooled estimates indicate strong
evidence that surgery and RT, each in comparison with
AM, reduce the incidence of prostate cancer death (Fig. 2),
metastatic disease (Fig. 3), disease progression, and the
onset of hormone treatment. There was no evidence that
either surgery or RT compared with AM reduced all-cause
death, nor evidence of a difference on any of the five
outcome measures when comparing surgery with RT.
In exploratory analyses, we combined the surgery group
and the RT treatment-received group, and compared out-
comes with AM. There was a reduction in prostate cancer-
specific mortality with radical treatment compared with AM
in the randomised cohort (hazard ratio = 0.34; 95% confi-
dence interval [CI] 0.13, 0.94) and the treatment choice cohort
(hazard ratio = 0.27; 95% CI 0.08, 0.91). Pooling of these two
estimates suggested a marked decrease in prostate cancerPlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.030mortality with radical treatment (hazard ratio = 0.31; 95% CI
0.14, 0.67; p = 0.003), although the small number of prostate
cancer deaths means that the absolute reduction is modest.
Urinary incontinence, as measured by patient-reported
pad use, was increased following surgery compared with
AM and RT (p < 0.001; Fig. 4 and Supplementary Table 3).
Six months after surgery, 55% reported daily use of pads,
reducing to 20% after 3 yr and remaining stable thereafter.
Pad use was negligible following RT but increased gradually
to 7% in the AM group. An increased proportion of men
reported nocturia in the 6 mo following RT (65%) before
stabilising at 30–40% for all men irrespective of manage-
ment (p < 0.001; Fig. 4 and Supplementary Table 4). RT and
surgery both reduced the proportion of men reporting
potency at 6 mo (18.5% and 5%, respectively). Although
there was some recovery by 2 yr, only 28–30% of men in the
RT group and 15% in the surgery group reported being
potent at 6 yr (p < 0.001; Fig. 4 and Supplementary Table 5).
More men in the AM group reported themselves as potent,ty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
Fig. 4 – Patient-reported incontinence pad use, nocturia,
potency, and bloody stools by active monitoring (green dash),
radical prostatectomy (red), and radiotherapy (blue) groups,
defined by treatment received. EPIC = Expanded Prostate Index
Composite; ICSmaleSF = International Continence Society Male
Short Form.
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(2019), https://doi.org/10.1016/j.eururo.2019.10.030but this reduced gradually over time, reflecting ageing and
receipt of radical treatment during follow-up. Following RT,
a small proportion of men (around 5%) experienced bloody
stools at least half the time, with this proportion maintained
over the 6-yr follow-up (p < 0.001; Fig. 4 and Supplemen-
tary Table 6).
4. Discussion
The analysis presented here compares groups according to
treatment received in two cohorts within a trial with uniform
initial recruitment: the randomised cohort that initially
agreed to randomisation, and the treatment choice cohort
that was eligible but declined randomisation and chose
treatment. For the prespecified comparison of groups defined
by treatment received within the randomised cohort, we
found no evidence of a difference in prostate cancer death
between the three treatments at a median follow-up of 10 yr,
which is in accord with the primary ITT analysis [2].
The exploratory analyses comparing outcomes between
groups defined by treatment received, in the combined and
treatment choice cohorts, gave results that were in broad
agreement with the ITT analysis [2]. However, when the
outcomes for the two cohorts were pooled, there was
evidence of a lower risk of prostate cancer death following
surgery and RT compared with AM, although the absolute
reduction in prostate cancer deaths with radical treatment
was modest. However, recent studies suggest that the use of
metastasis-free survival is a highly appropriate endpoint for
prostate cancer trials [19–21]; studies with both the ITT and
this comparison of groups defined by treatment received
confirmed the increased rates of metastasis-free survival in
the two radical treatment arms.
The four PROMs presented in this paper lead to the same
conclusions as the ITT analysis [3], with the results being
clearer. There was strong evidence of substantial and
persistent elevations in the rates of urinary incontinence
and erectile dysfunction following surgery, in the rates of
nocturia in the 12 mo following RT, and in the rates of erectile
dysfunction and bloody stools following RT. Men managed by
AM avoided the impacts caused by radical treatments,
although slow and gradual increases in urinary incontinence,
nocturia, and erectile dysfunction were reported during
follow-up, reflecting ageing and increased receipt of radical
treatments over time. We have previously noted the “trade-
off” that men with localised prostate cancer need to make
between side effects on urinary, bowel, and sexual function,
against reducing later risks of metastasis and progression,
and resulting impacts on quality and length of life [2,3].
The key limitation to analyses based on treatment
received rather than ITT is the potential for bias. Such groups
will differ in terms of occupation, and prognostic factors that
influence clinicians to advise patients to undergo specific
treatments. In both the randomised and the treatment choice
cohort, there was evidence that men with higher-risk disease
were more likely to be managed by radical treatments andty, Disease Progression, and Treatment-related Side Effects in
d Controlled Trial According to Treatment Received. Eur Urol
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biases, clinical outcomes were worse in the AM group.
We employed propensity score methods to control for
confounding due to imbalance in known prognostic factors.
However, such approaches do not control for unknown
factors, although confidence in the results reported here is
increased by three factors. Firstly, the similarity with the
primary ITT analysis from the RCT. Secondly, the direction of
confounding by known prognostic factors (eg, patients with
low-risk disease were more likely to be managed by AM)
means that known confounding cannot explain increased
prostate cancer-related events in the AM group. Thirdly, all-
cause death rates are comparable across the three
treatment-received groups, suggesting that a man's general
health did not underlie the selection biases.
A second limitation results from the natural history of
screen-detected and localised prostate cancer, requiring
studies with many years of follow-up during which clinical
practice evolves. Evaluation of men for AM has developed,
largely driven by changes in the diagnostic pathway, which
uses prebiopsy imaging using multiparametric magnetic
resonance imaging (mpMRI) scanning, transperineal biopsy,
and targeting of visible lesions. This will likely lead to a
reduction in the diagnosis of low-risk, low-volume prostate
cancer and an increase in the diagnosis of significant
cancers requiring early intervention [22,23].
The CAP trial of a single screening round using PSA
testing demonstrated that conventional diagnostic path-
ways miss cancers destined to be lethal. Many such men
have PSA levels below the conventional threshold for
referral, while diagnosing many low-risk tumours [24]. In
addition, the results of AM reported here may reflect that
some men choosing or being randomised to AM may not
have been recommended for this option on the basis of
current management that would include mpMRI [23]. De-
spite this limitation, and the low intensity of monitoring
primarily by PSA kinetics, mortality from prostate cancer
remained very low. Rates of change of management to
radical treatments in both ProtecT cohorts were in keeping
with previous active surveillance programmes reporting
approximately 30% of men receiving radical treatment
within 3 yr [25,26].
Treatments for progressing prostate cancer have also
improved markedly in recent years, and it is likely that this
has also contributed to the low prostate cancer mortality
rates observed in the trial [27].
5. Conclusions
The ProtecT primary ITT analysis, and analyses of the
randomised and treatment received cohorts according
to treatment received have confirmed that surgery and RT
reduce metastasis and progression compared with AM,
but impact sexual, urinary, and bowel functioning.
In addition, exploratory analyses suggest that radical
treatments may be associated with lower prostate
cancer mortality than AM, albeit the numbers of such
deaths were low irrespective of treatment. The findingsPlease cite this article in press as: Neal DE, et al. Ten-year Mortali
Men with Localised Prostate Cancer from the ProtecT Randomise
(2019), https://doi.org/10.1016/j.eururo.2019.10.030need to be considered in the context of potential biases
and confounding variables in the treatment received
analysis. Follow-up of these cohorts is continuing and
will clarify further the various trade-offs that need to be
weighed up when choosing treatment for localised
prostate cancer.
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